Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
The balance between the pro-apoptotic lipids ceramide and sphingosine and the pro-survival lipid sphingosine 1-phosphate (S1P) is termed the "sphingosine rheostat". Two isozymes, sphingosine kinase 1 and 2 (SK1 and SK2), are responsible for phosphorylation of pro-apoptotic sphingosine to form pro-survival S1P. We have previously reported the antitumor properties of an SK2 selective inhibitor, ABC294640, alone or in combination with the multikinase inhibitor sorafenib in mouse models of kidney carcinoma and pancreatic adenocarcinoma. Here we evaluated the combined antitumor effects of the aforementioned drug combination in two mouse models of hepatocellular carcinoma. Although combining the SK2 inhibitor, ABC294640, and sorafenib in vitro only afforded additive drug-drug effects, their combined antitumor properties in the mouse model bearing HepG2 cells mirrored effects previously observed in animals bearing kidney carcinoma and pancreatic adenocarcinoma cells. Combining ABC294640 and sorafenib led to a decrease in the levels of phosphorylated ERK in SK-HEP-1 cells, indicating that the antitumor effect of this drug combination is likely mediated through a suppression of the MAPK pathway in hepatocellular models. We also measured levels of S1P in the plasma of mice treated with two different doses of ABC294640 and sorafenib. We found decreases in the levels of S1P in plasma of mice treated daily with 100 mg/kg of ABC294640 for 5 weeks, and this decrease was not affected by co-administration of sorafenib. Taken together, these data support combining ABC294640 and sorafenib in clinical trials in HCC patients. Furthermore, monitoring levels of S1P may provide a pharmacodynamic marker of ABC294640 activity.
Drug Discovery Core; Hollings Cancer Center, Medical University of South Carolina, Charleston, USA.
Vladimir
V
Beljanski
Clayton S
CS
Lewis
Charles D
CD
Smith
D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001557:Benzenesulfonates / Q000494:pharmacology / Q000627:therapeutic use*; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005434:Flow Cytometry; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008246:Lysophospholipids / Q000097:blood; D051379:Mice; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use*; D000077157:Sorafenib; D013110:Sphingosine / Q000031:analogs & derivatives / Q000097:blood; D023041:Xenograft Model Antitumor Assays; D000099157:Sphingosine Kinase
D000218:Adamantane; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D008246:Lysophospholipids; D020928:Mitogen-Activated Protein Kinases; D009536:Niacinamide; D010671:Phenylurea Compounds; D017853:Phosphotransferases (Alcohol Group Acceptor); D011725:Pyridines; D000077157:Sorafenib; D013110:Sphingosine; D000099157:Sphingosine Kinase; C060506:sphingosine 1-phosphate; C548780:3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
Clin Liver Dis. 2010 Aug;14(3):461-76
20638025
Curr Opin Cell Biol. 2004 Dec;16(6):663-9
15530778
Cancer Biol Ther. 2008 Oct;7(10):1648-62
18787411
Autophagy. 2008 Nov;4(8):1042-53
18927491
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Apr 1;877(10):983-90
19285924
Recent Results Cancer Res. 2010;184:61-70
20072831
JAMA. 2010 Nov 17;304(19):2154-60
21081728
Autophagy. 2007 Jan-Feb;3(1):45-7
17035732
J Thorac Oncol. 2010 May;5(5):719-20
20421765
Cancer Lett. 2011 Feb 1;301(1):75-84
21078540
Biochim Biophys Acta. 2006 Dec;1758(12):2016-26
16996023
Oncology. 2010 Jul;78 Suppl 1:131-4
20616595
World J Gastroenterol. 2008 Jan 7;14(1):1-14
18176955
Oncogene. 2010 Sep 9;29(36):4989-5005
20639898
Cancer Res. 2003 Sep 15;63(18):5962-9
14522923
Invest New Drugs. 2011 Dec;29(6):1132-42
20473784
Exp Mol Pathol. 2007 Feb;82(1):1-11
16624283
Cancer Chemother Pharmacol. 2008 Feb;61(2):231-42
17429631
J Pharmacol Exp Ther. 2010 Apr;333(1):129-39
20061445
J Biol Chem. 2005 Nov 4;280(44):36865-72
16093248
Ann Surg Oncol. 2008 Apr;15(4):1008-14
18236117
Exp Biol Med (Maywood). 2009 Nov;234(11):1253-63
19546354
J Biol Chem. 2010 Apr 16;285(16):11818-26
20172858
Biotechnol J. 2009 Jul;4(7):1028-41
19579220
J Chin Med Assoc. 2010 May;73(5):262-4
20685594
Drugs Today (Barc). 2005 Dec;41(12):773-84
16474853
J Gastroenterol Hepatol. 2010 Nov;25(11):1739-46
21039835
J Clin Oncol. 2010 Sep 1;28(25):3994-4005
20679622
Cancer Res. 2010 Jan 15;70(2):440-6
20068163
Liver Int. 2009 Jan;29(1):10-7
19120940
J Cell Physiol. 2009 Dec;221(3):688-95
19711353
J Biochem Mol Biol. 2006 Mar 31;39(2):113-31
16584625
Br J Hosp Med (Lond). 2010 Aug;71(8):451-6
20852487
Biochim Biophys Acta. 2002 Dec 30;1585(2-3):193-201
12531554
J Pharmacol Exp Ther. 2010 May;333(2):454-64
20179157
J Lipid Res. 2009 Apr;50 Suppl:S91-6
19017611
Oncologist. 2009 Jan;14(1):67-9
19147690